Stockreport

Genentech's Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF MOGAD is a rare autoimmune disease of the central nervous system characterized by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe [Read more]